Ambros Therapeutics: Valuation, Funding & Investors
Ambros Therapeutics is a clinical-stage biotechnology company focused on the development of innovative and transformative medicines for diseases with high unmet medical need. The company's lead investigational program targets Complex Regional Pain Syndrome Type 1 (CRPS-1).
Leadership & Board
- Current Number of Employees
- 35
- Current LinkedIn Followers
- 1,811
Latest Estimated Valuation
- Total Amount Raised
- $125M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $125M
- Latest Funding Round
- Series A
Employee Trend
Ambros Therapeutics had 35 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
35Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
Ambros Therapeutics had 1,811 followers as of November 16, 2026. The number of followers increased by 13 (0.72%) week-over-week.
1,811Latest Followers Count
13(0.72%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Dec 16, 2025 | Series A | $125.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| RA Capital Management | Series A |
| Janus Henderson Investors | Series A |
| Balyasny Asset Management | Series A |
| Adage Capital Partners LP | Series A |
| Patient Square Capital's platform Enavate Sciences | Series A |
| Abiogen Pharma | Series A |
| Arkin Bio | Series A |
| Transhuman Capital | Series A |
Similar Companies
A snapshot of private companies similar to Ambros Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis









